Atara Biotherapeutics (ATRA) Payables (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Payables came in at $637000.0 in Q1 2026, down 53.97% YoY from $1.4 million in Q1 2025, and up 401.57% on a QoQ basis from $127000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Payables (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Payables data on file, last reported at $637000.0 in Q1 2026.
- Quarterly Payables fell 53.97% year-over-year to $637000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $637000.0 (down 53.97% YoY) and the FY2025 annual result came in at $127000.0, down 97.09% from the prior year.
- Payables advanced to $637000.0 in Q1 2026, from $127000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $12.8 million in Q2 2022 to a low of $127000.0 in Q4 2025.
- A 5-year average of $4.8 million and a median of $4.1 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2024 — Payables climbed 26.95% — and 2025, when it plunged 97.09%.
- Tracing ATRA's Payables over 5 years: stood at $6.9 million in 2022, then plunged by 46.38% to $3.7 million in 2023, then grew by 18.54% to $4.4 million in 2024, then sank by 97.09% to $127000.0 in 2025, then surged by 401.57% to $637000.0 in 2026.
- The last three Payables figures came in at $637000.0 (Q1 2026), $127000.0 (Q4 2025), and $318000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 35.57 Mn |
| 10 | Atara Biotherapeutics | 144.47 Mn | 127.92 Mn | 439,000.00 | 824,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 824,000.00 |
| Mar 31, 2026 | 637,000.00 |
| Dec 31, 2025 | 127,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 1.76 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 2.85 Mn |
| Dec 31, 2023 | 3.68 Mn |
| Sep 30, 2023 | 6.51 Mn |
| Jun 30, 2023 | 4.14 Mn |
| Mar 31, 2023 | 5.07 Mn |
| Dec 31, 2022 | 6.87 Mn |
| Sep 30, 2022 | 11.30 Mn |
| Jun 30, 2022 | 12.80 Mn |
| Mar 31, 2022 | 11.95 Mn |
| Dec 31, 2021 | 17.37 Mn |
| Sep 30, 2021 | 16.54 Mn |